Customising an international disease management model to the needs of individual countries: Application to upper gastrointestinal disease

PharmacoEconomics

Volumn 14, Issue SUPPL. 2, 1998, Pages 39-56

  Haiycox, Alan ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

AUSTRALIA; DRUG COST; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH ECONOMICS; MODEL; PRIORITY JOURNAL; RESOURCE MANAGEMENT; REVIEW; UNITED STATES; UPPER GASTROINTESTINAL TRACT;

DISEASE MANAGEMENT; ECONOMICS, PHARMACEUTICAL; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GERMANY; GREAT BRITAIN; HUMANS; PRIMARY HEALTH CARE; SWEDEN; SWITZERLAND;

EID: 0031763602     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814002-00005     Document Type: Review

References (2)

1. Freemantle N, Bloor K. Lessons from international experience in controlling pharmaceutical expenditure. I. Influencing patients. BMJ 1996; 312 (7044): 1469-71
2. Menzim J, Oster S, Davies L, et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Int J Technol Assess Health Care 1996; 12 (1): 52-61